Drugs that contain Everolimus

1. List of Afinitor drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778962 NOVARTIS Treatment of solid tumors with rapamycin derivatives
Feb, 2022

(11 months ago)

US8436010 NOVARTIS Treatment of solid tumors with rapamycin derivatives
Feb, 2022

(11 months ago)

US8778962

(Pediatric)

NOVARTIS Treatment of solid tumors with rapamycin derivatives
Aug, 2022

(5 months ago)

US8436010

(Pediatric)

NOVARTIS Treatment of solid tumors with rapamycin derivatives
Aug, 2022

(5 months ago)

US8410131 NOVARTIS Cancer treatment
Nov, 2025

(2 years from now)

US8410131

(Pediatric)

NOVARTIS Cancer treatment
May, 2026

(3 years from now)

US9006224 NOVARTIS Neuroendocrine tumor treatment
Jul, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Feb 26, 2023

Market Authorisation Date: 30 March, 2009

Treatment: Treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected.; Treatment of advanced hormone receptor positive, her2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole; Treatment of solid excretory system tumors; Advanced renal cell carcinoma (rcc), after failure of treatment with sunitinib or sorafenib; Treatment of patients with progessive neuroendocrine tumors of pancreatic origin (pnet) that are unresectable, locally advanced or metastatic

Dosage: TABLET;ORAL

How can I launch a generic of AFINITOR before it's patent expiration?
More Information on Dosage

2. List of Afinitor Disperz drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778962 NOVARTIS PHARM Treatment of solid tumors with rapamycin derivatives
Feb, 2022

(11 months ago)

US8778962

(Pediatric)

NOVARTIS PHARM Treatment of solid tumors with rapamycin derivatives
Aug, 2022

(5 months ago)

US8617598 NOVARTIS PHARM Pharmaceutical compositions comprising colloidal silicon dioxide
Sep, 2022

(4 months ago)

US8617598

(Pediatric)

NOVARTIS PHARM Pharmaceutical compositions comprising colloidal silicon dioxide
Mar, 2023

(a month from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 10, 2025

Market Authorisation Date: 29 August, 2012

Treatment: Treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected.; Adjunctive treatment of patients with tsc-associated partial-onset seizures

Dosage: TABLET, FOR SUSPENSION;ORAL

How can I launch a generic of AFINITOR DISPERZ before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic